Orexo AB has announced that it sold Abstral (fentanyl) Sublingual Tablets in the United States to Galena Biopharma, Inc. Under...
Orexo AB have regained from 1 January 2013 US rights to market Abstral (fentanyl citrate sublingual) from Kyowa Hakko Kirin/ProStraken....
Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain.
The FDA has approved Ionsys (fentanyl iontophoretic transdermal system), from The Medicines Company, the first needle-free, patient-controlled, pre-programmed fentanyl delivery...